Study of Carfilzomib, Daratumumab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma.

NCT03158688 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

466

Enrollment

INDUSTRY

Sponsor class

Conditions

Relapsed Multiple Myeloma
Refractory Multiple Myeloma

Interventions

DRUG: Dexamethasone
DRUG: Daratumumab
DRUG: Carfilzomib

Sponsor

Amgen